Patent 10995121 was granted and assigned to Oregon Health & Science University on May, 2021 by the United States Patent and Trademark Office.
Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.